Table 1.
Baseline Characteristics for all 106 transplanted patients
| Characteristics | Total Transplanted (N=106) |
|---|---|
|
| |
| Demographics | |
|
| |
| Age (year) | |
| Mean ± SD | 11.9 ± 6.20 |
|
| |
| Male Gender | 70 (66.0) |
|
| |
|
| |
| Race | |
|
| |
| White | 77 (72.6) |
|
| |
| Black or African American | 14 (13.2) |
|
| |
| Asian | 8 (7.5) |
|
| |
| Other | 2 (1.9) |
|
| |
| Unknown or Not Reported | 5 (4.7) |
|
| |
|
| |
| Ethnicity | |
|
| |
| Hispanic or Latino | 47 (44.3) |
|
| |
| Not Hispanic or Latino | 53 (50.0) |
|
| |
| Unknown or Not Reported | 6 (5.7) |
|
| |
|
| |
| Height and Weight | |
|
| |
| Height Z scores | |
|
| |
| Mean ± SD | −1.2 ± 1.70 |
|
| |
|
| |
| Weight Z scores | |
|
| |
| Mean ± SD | −0.5 ± 1.55 |
|
| |
|
| |
|
| |
| BMI Z scores | |
|
| |
| Mean ± SD | −0.2 ± 4.19 |
|
| |
|
| |
| Use of Induction Therapy | |
|
| |
| Basiliximab | 36 (34.0) |
|
| |
| Daclizumab | 45 (42.5) |
|
| |
| Thymoglobulin | 27 (25.5) |
|
| |
|
| |
| Use of Maintenance Therapy | |
|
| |
| Tacrolimus | 105 (99.1) |
|
| |
| MMF | 104 (98.1) |
|
| |
| Prednisone | 63 (59.4) |
|
| |
| Sirolimus | 20 (18.9) |
|
| |
| Azathioprine | 7 (6.6) |
|
| |
| Cyclosporine | 2 (1.9) |
|
| |
| Leflunomide | 1 (0.9) |
|
| |
|
| |
| Clinical Infection | |
|
| |
| Bacterial | 22 (20.8) |
|
| |
| Fungal | 3 (2.8) |
|
| |
| Viral | 27 (25.5) |
|
| |
|
| |
| Protozoal | 2 (1.9) |
|
| |
| Parasitic | 1 (0.9) |
|
| |
|
| |
| Viremia by PCR | |
|
| |
|
| |
| CMV+ by Local or Central PCR | 24 (22.6) |
|
| |
| EBV+ by Local or Central PCR | 36 (34.0) |
|
| |
| BKV+ by Local or Central PCR | 24 (22.6) |
|
| |
| Other+ by Central PCR [1] | 39 (36.8) |
|
| |
|
| |
| Clinical Outcomes | |
|
| |
| Alloimmune Failure | 40 (37.7) |
|
| |
| BPAR incl Borderline | 24 (22.6) |
|
| |
| denovo DSA | 23 (21.7) |
|
| |
| Viremia | 77 (72.6) |
|
| |
|
| |
[1]
Other viruses include adeno, HHV, and JCV.